Research programme: K 252a derivatives - Bio3 Research/Creabilis Therapeutics

Drug Profile

Research programme: K 252a derivatives - Bio3 Research/Creabilis Therapeutics

Alternative Names: CT 335; CT 336; K252a derivatives

Latest Information Update: 15 Dec 2016

Price : $50

At a glance

  • Originator Kyowa Hakko
  • Class Antiallergics; Carbazoles
  • Mechanism of Action HMGB1 protein inhibitors; Protein tyrosine kinase inhibitors; TrkA receptor antagonists; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Behcet's syndrome; Coronary artery restenosis; Psoriasis

Most Recent Events

  • 06 Dec 2016 Creabilis Therapeutics has been acquired by Sienna Biopharmaceuticals
  • 14 Apr 2010 Discontinued - Preclinical for Behcet's syndrome in Italy (Parenteral)
  • 14 Apr 2010 Discontinued - Preclinical for Coronary artery restenosis in Italy (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top